Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab

Emicizumab is a bispecific monoclonal antibody that substitutes for the function of missing or deficient factor VIII (FVIII) in people with hemophilia A (PwHA). Long-term safety and efficacy of emicizumab have been demonstrated in several clinical trials. Nevertheless, in the first of these, three c...

Descripción completa

Detalles Bibliográficos
Autores principales: Valls, Raquel, Wagg, Jonathan, Paz-Priel, Ido, Man, Gabriel, Artigas, Laura, Jaccard, Georges, Coma, Mireia, Schmitt, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284911/
https://www.ncbi.nlm.nih.gov/pubmed/37344529
http://dx.doi.org/10.1038/s41598-023-36891-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284911/
https://www.ncbi.nlm.nih.gov/pubmed/37344529
http://dx.doi.org/10.1038/s41598-023-36891-x

Ejemplares similares